Company Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:20:01 2025-06-24 EDT			5-day change	1st Jan Change
53.32 ^USD	-0.07%		-2.30%	+39.74%

06-17	Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target	MT
06-16	Protagonist Therapeutics, Inc. - Special Call

Business description: Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Companyâs clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Companyâs Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (Î±4Î²7) specific integrin antagonist for inflammatory bowel disease (IBD).

Number of employees: 124

Sales by Activity: Protagonist Therapeutics, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Biotechnology (Startups)	28.63M	27.36M	26.58M	60M	434M

See all business segments

Geographical breakdown of sales: Protagonist Therapeutics, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
United States	28.63M	27.36M	26.58M	60M	434M

See all geographic segments

Executive Committee: Protagonist Therapeutics, Inc.

Manager	Title	Age	Since
Dinesh Patel CEO	Chief Executive Officer	68	2008-11-30
Asif Ali DFI	Director of Finance/CFO	51	2022-04-17
Newman Yeilding CTO	Chief Tech/Sci/R&D Officer	-	2025-01-01
Samuel Saks CTO	Chief Tech/Sci/R&D Officer	70	2019-05-07
Arturo Molina CTO	Chief Tech/Sci/R&D Officer	66	2022-11-06

See PROTAGONIST THERAPEUTICS, INC. governance

Composition of the Board of Directors: Protagonist Therapeutics, Inc.

Director	Title	Age	Since
Dinesh Patel BRD	Director/Board Member	68	2008-11-30
Harold Selick CHM	Chairman	70	2014-03-18
William Waddill BRD	Director/Board Member	68	2016-06-30
Lewis Williams BRD	Director/Board Member	75	2017-06-07
Bryan Giraudo BRD	Director/Board Member	49	2018-05-15
Sarah O'Dowd BRD	Director/Board Member	75	2020-08-11

Composition of the Board of Directors

Shareholders: Protagonist Therapeutics, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 15.17 %	9,310,597	15.17 %	442 M $
Farallon Capital Management LLC 9.949 %	6,107,006	9.949 %	290 M $
RTW Investments LP 9.317 %	5,719,415	9.317 %	272 M $
Vanguard Fiduciary Trust Co. 6.968 %	4,277,218	6.968 %	203 M $
BVF Partners LP 5.231 %	3,211,041	5.231 %	152 M $

List of PROTAGONIST THERAPEUTICS, INC. shareholders

Company details: Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.

7707 Gateway Boulevard Suite 140

94560-1160, Newark

http://www.protagonist-inc.com

address Protagonist Therapeutics, Inc.(PTGX)

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
PROTAGONIST THERAPEUTICS, INC.	-0.07%	-2.30%	+68.51%	+494.05%	3.31B
LONZA GROUP AG	+1.60%	+1.82%	+17.02%	+11.15%	48.77B
BEONE MEDICINES LTD.	+3.32%	+4.59%	+66.98%	+49.31%	30.55B
IQVIA HOLDINGS INC.	+2.05%	+2.59%	-26.16%	-26.06%	26.84B
CELLTRION, INC.	+1.38%	-0.37%	-0.60%	+14.06%	25.49B
EUROFINS SCIENTIFIC SE	+1.44%	-0.43%	+36.54%	-23.38%	12.34B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-2.07%	-70.87%	+25,115.87%	+2,676.09%	11.72B
ICON PUBLIC LIMITED COMPANY	+0.59%	+4.43%	-53.25%	-32.86%	11.71B
TEMPUS AI, INC.	+2.48%	-3.64%	+166.91%	-	11.37B
ASCENDIS PHARMA A/S	+1.89%	+3.67%	+38.53%	+96.77%	10.61B
Average	+1.22%	-8.23%	+2,543.04%	+362.13%	19.27B
Weighted average by Cap.	+1.62%	-5.60%	+1,550.85%	+193.33%